LUGPA CEO Celeste Kirschner, CAE, MHSA, outlines the association's top 2027 priorities: fee schedule reform, site-neutral payments, prior authorization, and practice consolidation. In this Q&A, ...

Prof Declan Murphy discusses PROTEUS pathologic responses with apalutamide plus ADT and their implications for future treatment strategies. In this video, Declan Murphy, MB, BCH, BaO, FRACS, FRCS, ...

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO ...

María Natalia Gandur Quiroga, MD, MSc, highlights treatment selection, negative trials, and implementation in GU oncology as 3 key themes emerging from ASCO 2026. Alan Bryce, MD, breaks down the key ...

Cycling has multiple benefits, and steps can be taken to prevent genitourinary injury. Bicycling across the globe is increasing as a means of exercise and transportation. Clinicians need to be ...

The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...

"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.

Pre-operative counseling should frame vasectomy as intended permanent contraception, individualized to reproductive goals, and can be delivered virtually or in person while directly addressing ...

The AUSCO trial showed a 94% success rate in achieving significant continence improvement in men with SUI using the artificial urinary sphincter. The study found no device infections and low ...

Enzalutamide plus ADT significantly reduced the risk of radiographic progression or death and castration resistance compared to darolutamide plus ADT in mHSPC patients. The MAIC analysis provided a ...

Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...

"Based on the LEA and S1011 trials, it has become clear that patients do not benefit from an extended LND, and a standard bilateral pelvic LND is the standard of care," write Amir Soltani-Tehrani, MD, ...